AI Article Synopsis
- Interstitial lung disease (ILD) is a serious complication of connective tissue disease (CTD) and significantly impacts patient mortality rates.
- Timely identification and management of ILD are essential to improve outcomes for patients with CTD.
- Recent research focuses on both traditional blood tests and advanced -omic biomarkers to better diagnose and predict disease progression in CTD-ILD patients.
Article Abstract
Interstitial lung disease (ILD) complicates connective tissue disease (CTD) with variable incidence and is a leading cause of death in these patients. To improve CTD-ILD outcomes, early recognition and management of ILD is critical. Blood-based and radiologic biomarkers that assist in the diagnosis CTD-ILD have long been studied. Recent studies, including -omic investigations, have also begun to identify biomarkers that may help prognosticate such patients. This review provides an overview of clinically relevant biomarkers in patients with CTD-ILD, highlighting recent advances to assist in the diagnosis and prognostication of CTD-ILD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rdc.2024.03.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!